Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors.

Yap TA, Winter JN, Giulino-Roth L, Longley J, Lopez J, Michot JM, Leonard JP, Ribrag V, McCabe MT, Creasy CL, Stern M, Pene Dumitrescu T, Wang X, Frey S, Carver J, Horner T, Oh C, Khaled A, Dhar A, Johnson PWM.

Clin Cancer Res. 2019 Aug 30. doi: 10.1158/1078-0432.CCR-18-4121. [Epub ahead of print]

PMID:
31471312
2.

PARP inhibition - opportunities in pancreatic cancer.

Pant S, Maitra A, Yap TA.

Nat Rev Clin Oncol. 2019 Oct;16(10):595-596. doi: 10.1038/s41571-019-0257-6. No abstract available.

PMID:
31332344
3.

Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy.

Fang Y, McGrail DJ, Sun C, Labrie M, Chen X, Zhang D, Ju Z, Vellano CP, Lu Y, Li Y, Jeong KJ, Ding Z, Liang J, Wang SW, Dai H, Lee S, Sahni N, Mercado-Uribe I, Kim TB, Chen K, Lin SY, Peng G, Westin SN, Liu J, O'Connor MJ, Yap TA, Mills GB.

Cancer Cell. 2019 Jun 10;35(6):851-867.e7. doi: 10.1016/j.ccell.2019.05.001.

PMID:
31185210
4.

Improving attribution of adverse events in oncology clinical trials.

George GC, Barata PC, Campbell A, Chen A, Cortes JE, Hyman DM, Jones L, Karagiannis T, Klaar S, Le-Rademacher JG, LoRusso P, Mandrekar SJ, Merino DM, Minasian LM, Mitchell SA, Montez S, O'Connor DJ, Pettit S, Silk E, Sloan JA, Stewart M, Takimoto CH, Wong GY, Yap TA, Cleeland CS, Hong DS.

Cancer Treat Rev. 2019 Jun;76:33-40. doi: 10.1016/j.ctrv.2019.04.004. Epub 2019 Apr 25. Review.

PMID:
31108240
5.

The DNA Damaging Revolution: PARP Inhibitors and Beyond.

Yap TA, Plummer R, Azad NS, Helleday T.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:185-195. doi: 10.1200/EDBK_238473. Epub 2019 May 17. Review.

6.

PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers.

Pilié PG, Gay CM, Byers LA, O'Connor MJ, Yap TA.

Clin Cancer Res. 2019 Jul 1;25(13):3759-3771. doi: 10.1158/1078-0432.CCR-18-0968. Epub 2019 Feb 13. Review.

PMID:
30760478
7.

Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology.

Hobbs BP, Barata PC, Kanjanapan Y, Paller CJ, Perlmutter J, Pond GR, Prowell TM, Rubin EH, Seymour LK, Wages NA, Yap TA, Feltquate D, Garrett-Mayer E, Grossman W, Hong DS, Ivy SP, Siu LL, Reeves SA, Rosner GL.

J Natl Cancer Inst. 2019 Feb 1;111(2):118-128. doi: 10.1093/jnci/djy196.

8.

Development of PARP and Immune-Checkpoint Inhibitor Combinations.

Stewart RA, Pilié PG, Yap TA.

Cancer Res. 2018 Dec 15;78(24):6717-6725. doi: 10.1158/0008-5472.CAN-18-2652. Epub 2018 Nov 29. Review.

PMID:
30498083
9.

PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.

Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, Yap TA, Mills GB, Peng G.

Cancer Res. 2019 Jan 15;79(2):311-319. doi: 10.1158/0008-5472.CAN-18-1003. Epub 2018 Nov 27.

PMID:
30482774
10.

Moving Precision Oncology Forward Amid Myths and Misconceptions.

Janku F, Hess KR, Yap TA.

JAMA Oncol. 2018 Dec 1;4(12):1788-1789. doi: 10.1001/jamaoncol.2018.5064. No abstract available.

PMID:
30419079
11.

Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma.

Al-Saffar NMS, Troy H, Wong Te Fong AC, Paravati R, Jackson LE, Gowan S, Boult JKR, Robinson SP, Eccles SA, Yap TA, Leach MO, Chung YL.

Br J Cancer. 2018 Oct;119(9):1118-1128. doi: 10.1038/s41416-018-0242-3. Epub 2018 Oct 31.

12.

State-of-the-art strategies for targeting the DNA damage response in cancer.

Pilié PG, Tang C, Mills GB, Yap TA.

Nat Rev Clin Oncol. 2019 Feb;16(2):81-104. doi: 10.1038/s41571-018-0114-z. Review.

PMID:
30356138
13.

Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre.

O'Carrigan B, Lim JSJ, Jalil A, Harris SJ, Papadatos-Pastos D, Banerji U, Lopez J, de Bono JS, Yap TA.

Br J Cancer. 2018 Oct;119(8):922-927. doi: 10.1038/s41416-018-0290-8. Epub 2018 Oct 15.

14.

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors.

O'Brien MER, Sarker D, Bhosle J, Thillai K, Yap TA, Uttenreuther-Fischer M, Pemberton K, Jin X, Wiebe S, de Bono J, Spicer J.

Cancer Chemother Pharmacol. 2018 Nov;82(5):757-766. doi: 10.1007/s00280-018-3661-1. Epub 2018 Aug 7.

15.

Targeting gamma secretase: has progress moved up a Notch?

Ileana Dumbrava EE, Mills GB, Yap TA.

Ann Oncol. 2018 Sep 1;29(9):1889-1891. doi: 10.1093/annonc/mdy307. No abstract available.

PMID:
30084907
16.

Combination drug development in BRAF mutant colorectal cancer.

Lam M, Pant S, Yap TA.

Oncoscience. 2018 Apr 29;5(3-4):51-53. doi: 10.18632/oncoscience.399. eCollection 2018 Mar. No abstract available.

17.

Challenges with biomarkers in cancer drug discovery and development.

Ileana Dumbrava E, Meric-Bernstam F, Yap TA.

Expert Opin Drug Discov. 2018 Aug;13(8):685-690. doi: 10.1080/17460441.2018.1479740. Epub 2018 May 24. No abstract available.

PMID:
29792354
18.

Untying the gordion knot of targeting MET in cancer.

Raghav K, Bailey AM, Loree JM, Kopetz S, Holla V, Yap TA, Wang F, Chen K, Salgia R, Hong D.

Cancer Treat Rev. 2018 May;66:95-103. doi: 10.1016/j.ctrv.2018.04.008. Epub 2018 Apr 26. Review.

PMID:
29730462
19.

Introduced bullfrog facilitates pathogen invasion in the western United States.

Yap TA, Koo MS, Ambrose RF, Vredenburg VT.

PLoS One. 2018 Apr 16;13(4):e0188384. doi: 10.1371/journal.pone.0188384. eCollection 2018.

20.

BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency.

Sun C, Yin J, Fang Y, Chen J, Jeong KJ, Chen X, Vellano CP, Ju Z, Zhao W, Zhang D, Lu Y, Meric-Bernstam F, Yap TA, Hattersley M, O'Connor MJ, Chen H, Fawell S, Lin SY, Peng G, Mills GB.

Cancer Cell. 2018 Mar 12;33(3):401-416.e8. doi: 10.1016/j.ccell.2018.01.019.

21.

Targeting the PI3K pathway in cancer: are we making headway?

Janku F, Yap TA, Meric-Bernstam F.

Nat Rev Clin Oncol. 2018 May;15(5):273-291. doi: 10.1038/nrclinonc.2018.28. Epub 2018 Mar 6. Review.

PMID:
29508857
22.

Precision Oncology Decision Support: Current Approaches and Strategies for the Future.

Kurnit KC, Dumbrava EEI, Litzenburger B, Khotskaya YB, Johnson AM, Yap TA, Rodon J, Zeng J, Shufean MA, Bailey AM, Sánchez NS, Holla V, Mendelsohn J, Shaw KM, Bernstam EV, Mills GB, Meric-Bernstam F.

Clin Cancer Res. 2018 Jun 15;24(12):2719-2731. doi: 10.1158/1078-0432.CCR-17-2494. Epub 2018 Feb 2. Review.

23.

Efficacy and Toxic Effects of Cancer Immunotherapy Combinations-A Double-edged Sword.

Tang C, Jiang W, Yap TA.

JAMA Oncol. 2018 Aug 1;4(8):1116-1117. doi: 10.1001/jamaoncol.2017.4606. No abstract available.

PMID:
29327039
24.

High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy.

Perez-Lopez R, Roda D, Jimenez B, Brown J, Mateo J, Carreira S, Lopez J, Banerji U, Molife LR, Koh DM, Kaye SB, de Bono JS, Tunariu N, Yap TA.

Oncotarget. 2017 Nov 6;8(61):104430-104443. doi: 10.18632/oncotarget.22303. eCollection 2017 Nov 28.

25.

Precision oncology: East meets West.

Subbiah V, Rodon J, Yap TA.

Int J Cancer. 2018 May 1;142(9):1734-1737. doi: 10.1002/ijc.31218. Epub 2018 Jan 4. No abstract available.

26.

Precision Medicine: Progress, Pitfalls, and Promises.

Pilié PG, LoRusso PM, Yap TA.

Mol Cancer Ther. 2017 Dec;16(12):2641-2644. doi: 10.1158/1535-7163.MCT-17-0904. No abstract available.

27.

The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers.

Vishwanathan K, Dickinson PA, Bui K, Cassier PA, Greystoke A, Lisbon E, Moreno V, So K, Thomas K, Weilert D, Yap TA, Plummer R.

J Clin Pharmacol. 2018 Apr;58(4):474-484. doi: 10.1002/jcph.1035. Epub 2017 Nov 26.

PMID:
29178442
28.

Batrachochytrium salamandrivorans and the Risk of a Second Amphibian Pandemic.

Yap TA, Nguyen NT, Serr M, Shepack A, Vredenburg VT.

Ecohealth. 2017 Dec;14(4):851-864. doi: 10.1007/s10393-017-1278-1. Epub 2017 Nov 16. Review.

PMID:
29147975
29.

A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.

Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, Zheng X, Chen K, Tapia C, Tarco E, Eterovic AK, Black DM, Litton JK, Yap TA, Tripathy D, Mills GB, Meric-Bernstam F.

Clin Cancer Res. 2017 Nov 1;23(21):6468-6477. doi: 10.1158/1078-0432.CCR-17-0615.

30.

Development of Molecularly Driven Targeted Combination Strategies.

Yap TA, Rodon J.

Oncologist. 2017 Dec;22(12):1421-1423. doi: 10.1634/theoncologist.2017-0402. Epub 2017 Oct 16. No abstract available.

31.

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments.

Minchom A, Thavasu P, Ahmad Z, Stewart A, Georgiou A, O'Brien MER, Popat S, Bhosle J, Yap TA, de Bono J, Banerji U.

PLoS One. 2017 Oct 5;12(10):e0186106. doi: 10.1371/journal.pone.0186106. eCollection 2017.

32.

Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?

Capelan M, Roda D, Geuna E, Rihawi K, Bodla S, Kaye SB, Bhosle J, Banerji U, O'Brien M, de Bono JS, Popat S, Yap TA.

Lung Cancer. 2017 Sep;111:6-11. doi: 10.1016/j.lungcan.2017.06.005. Epub 2017 Jun 15.

33.

Novel insights into mesothelioma biology and implications for therapy.

Yap TA, Aerts JG, Popat S, Fennell DA.

Nat Rev Cancer. 2017 Jul 25;17(8):475-488. doi: 10.1038/nrc.2017.42. Review.

PMID:
28740119
34.

Targeting ATR in cancer medicine.

Sundar R, Brown J, Ingles Russo A, Yap TA.

Curr Probl Cancer. 2017 Jul - Aug;41(4):302-315. doi: 10.1016/j.currproblcancer.2017.05.002. Epub 2017 May 17. Review.

PMID:
28662958
35.

Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies.

Sundar R, Hong DS, Kopetz S, Yap TA.

Cancer Discov. 2017 Jun;7(6):558-560. doi: 10.1158/2159-8290.CD-17-0087.

36.

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.

Rafii S, Gourley C, Kumar R, Geuna E, Ern Ang J, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA.

Oncotarget. 2017 Jul 18;8(29):47154-47160. doi: 10.18632/oncotarget.17005.

37.

Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer.

Sundar R, Chénard-Poirier M, Collins DC, Yap TA.

Front Med (Lausanne). 2017 Apr 10;4:39. doi: 10.3389/fmed.2017.00039. eCollection 2017. Review.

38.

Circulating tumor DNA-From bench to bedside.

Lim JSJ, Janku F, Yap TA.

Curr Probl Cancer. 2017 May - Jun;41(3):212-221. doi: 10.1016/j.currproblcancer.2017.02.005. Epub 2017 Mar 1.

PMID:
28416241
39.

Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer.

Dolly SO, Collins DC, Sundar R, Popat S, Yap TA.

Drugs. 2017 May;77(8):813-827. doi: 10.1007/s40265-017-0732-2. Review.

PMID:
28378229
40.

Precision medicine in oncology.

Takebe N, Yap TA.

Curr Probl Cancer. 2017 May - Jun;41(3):163-165. doi: 10.1016/j.currproblcancer.2017.01.001. Epub 2017 Jan 24. No abstract available.

PMID:
28372822
41.

Extracranial Soft-Tissue Tumors: Repeatability of Apparent Diffusion Coefficient Estimates from Diffusion-weighted MR Imaging.

Winfield JM, Tunariu N, Rata M, Miyazaki K, Jerome NP, Germuska M, Blackledge MD, Collins DJ, de Bono JS, Yap TA, deSouza NM, Doran SJ, Koh DM, Leach MO, Messiou C, Orton MR.

Radiology. 2017 Jul;284(1):88-99. doi: 10.1148/radiol.2017161965. Epub 2017 Mar 16.

42.

Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.

George A, Kristeleit R, Rafii S, Michie CO, Bowen R, Michalarea V, van Hagen T, Wong M, Rallis G, Molife LR, Lopez J, Banerji U, Banerjee SN, Gore ME, de Bono JS, Kaye SB, Yap TA.

Eur J Cancer. 2017 May;76:52-59. doi: 10.1016/j.ejca.2017.01.020. Epub 2017 Mar 6.

PMID:
28273485
43.

Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.

Papadatos-Pastos D, Roda D, De Miguel Luken MJ, Petruckevitch A, Jalil A, Capelan M, Michalarea V, Lima J, Diamantis N, Bhosle J, Molife LR, Banerji U, de Bono JS, Popat S, O'Brien MER, Yap TA.

Eur J Cancer. 2017 Apr;75:56-62. doi: 10.1016/j.ejca.2016.12.026. Epub 2017 Feb 17.

PMID:
28214659
44.

Targeting the PD-1/PD-L1 axis in non-small cell lung cancer.

Kumar R, Collins D, Dolly S, McDonald F, O'Brien MER, Yap TA.

Curr Probl Cancer. 2017 Mar - Apr;41(2):111-124. doi: 10.1016/j.currproblcancer.2016.12.002. Epub 2016 Dec 23. Review.

PMID:
28214087
45.

Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.

Brown JS, O'Carrigan B, Jackson SP, Yap TA.

Cancer Discov. 2017 Jan;7(1):20-37. doi: 10.1158/2159-8290.CD-16-0860. Epub 2016 Dec 21. Review.

46.

Targeting MET Exon 14 Skipping Alterations: Has Lung Cancer MET Its Match?

Yap TA, Popat S.

J Thorac Oncol. 2017 Jan;12(1):12-14. doi: 10.1016/j.jtho.2016.10.019. No abstract available.

47.

Emerging biomarkers for PD-1 pathway cancer therapy.

Lim JS, Sundar R, Chénard-Poirier M, Lopez J, Yap TA.

Biomark Med. 2017 Jan;11(1):53-67. Epub 2016 Dec 12. Review.

PMID:
27936870
48.

Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics.

Collins DC, Sundar R, Lim JSJ, Yap TA.

Trends Pharmacol Sci. 2017 Jan;38(1):25-40. doi: 10.1016/j.tips.2016.10.012. Epub 2016 Nov 18. Review.

PMID:
27871777
49.

Emerging strategies for the treatment of advanced small cell lung cancer.

Lim JS, Collins D, Yap TA.

J Thorac Dis. 2016 Oct;8(10):E1249-E1253. No abstract available.

50.

Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer.

Yap TA, Macklin-Doherty A, Popat S.

Eur J Cancer. 2017 Jan;70:12-21. doi: 10.1016/j.ejca.2016.10.014. Epub 2016 Nov 17. Review.

PMID:
27866095

Supplemental Content

Support Center